| Description | Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that exhibits directed activity against tumors. By activating antigen-presenting cells, such as dendritic cells (DC), it triggers the initiation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and destruction of tumors by tumor-specific T cells and remodels the tumor-infiltrating myeloid microenvironment [1] [2]. |
| molecular weight | N/A |
| CAS | 2055640-86-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |